NEW YORK, Oct. 3, 2017 /PRNewswire/ -- According to Stratistics MRC, the Global Cancer Diagnostics market is expected to grow from $8.54 billion in 2016 to reach $22.41 billion by 2023 with a CAGR of 14.8 %.
Read the full report: https://www.reportlinker.com/p05126471Increasing incidence of cancer diseases, growing awareness about health care, and recent technological advancements in diagnostic devices are some of the factors propelling the
market growth. In addition, favorable government reimbursement policies, increasing investments in research and development activities are some other factors boosting the market growth during the forecast period. On the other hand, high costs of diagnostic devices, strict regulations for new product approvals are the factors limiting the market growth. Globally, cancer is the most emerging disease in recent times. Cervical, breast, liver, blood, kidney, colorectal, pancreatic, ovarian, melanoma, and lung cancers are types of cancers persisting in humans. Diagnosing at early stage can cure the disease and limit the disease severity. Research institutes have the high adoption rate of cancer diagnostic devices due to heavy funding from government and private institutions. North America is estimated to be the dominant one among all, due to developed healthcare infrastructure, government initiatives towards public health care that are expected to drive this dominance. Asia Pacific region is predicted to grow at higher CAGR during the forecast period. The growth is attributed to rise in medical tourism market, increase in prevalence of cancer disease in countries such as Japan, China, and India are favoring the Asia Pacific market growth. Some of the key players in global Cancer Diagnostics market include Abbott Diagnostics, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMérieux, C.R. Bard, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare (A Subsidiary of General Electric Company), Hologic,Inc., Illumina, Inc., Koninklijke Philips N.V., Qiagen, Roche Diagnostics, Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc. Technologies Covered: • Instrument-Based • Platform-Based Diagnostics • Tumor Biomarkers Tests Applications Covered: • Cervical Cancer • Breast Cancer • Liver Cancer • Blood Cancer • Kidney Cancer • Colorectal Cancer • Pancreatic Cancer • Ovarian Cancer • Melanoma • Lung Cancer • Other Cancers End Users Covered: • Cancer Research Institutes • Diagnostic Laboratories • Hospital Associated Labs • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o UK o Italy o France o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • South America o Argentina o Brazil o Chile o Rest of South America • Middle East & Africa o Saudi Arabia o UAE o Qatar o South Africa o Rest of Middle East & Africa What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancementsRead the full report: https://www.reportlinker.com/p05126471 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. https://www.reportlinker.com __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/cancer-diagnostics---global-market-outlook-2017-2023-300530228.html